Business
Spectral Medical To Present At Microcap Rodeo's Annual Winter Wonderland- Best Ideas Virtual Investor Conference Today
TORONTO, ON / ACCESSWIRE / February 22, 2023 / Spectral Medical Inc. ("Spectral" or the "Company"...
About this update from Spectral Medical Inc
[{"type":"text","content":"Spectral Medical To Present At Microcap Rodeo's Annual Winter Wonderland- Best Ideas Virtual Investor Conference TodayTORONTO, ON / ACCESSWIRE / February 22, 2023 / Spectral Medical Inc. (\"Spectral\" or the \"Company\") (TSX:EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has been invited to present at MicroCap Rodeo's Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is being held virtually on February 21st - 24th, 2023.Chris Seto, Chief Executive Officer of Spectral Medical, and Dr. John Kellum, Chief Medical Officer of Spectral Medical, are scheduled to present today, Wednesday, February 22, 2023 at 4:30 p.m. Eastern Time. Management will also host one-on-one meetings with qualified investors throughout the conference.To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected] can register here.About the MicroCap Rodeo Winter Wonderland Best Ideas ConferenceThe MicroCap Rodeo is back with its Third Annual Winter Wonderland Best Ideas Conference. This conference is a virtual conference that brings you the top 37 best ideas. Qualified institutional investors recommended each of the 37 companies represented as one of their best ideas. Those of you who attended the 2019 MicroCap Rodeo in Austin, Texas, know that we're focused on alpha.About SpectralSpectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (\"PMX\"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 340,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxemic septic shock. Approximately 330,000 patients are diagnosed with s...